DATATRAK and Top 5 CRO Enact Multi-Year Enterprise Agreement

CLEVELAND, Dec. 3, 2014 /PRNewswire/ -- DATATRAK International, Inc. (OTCQX: DTRK), the leader in developing cloud-based, unified eClinical^® technologies for the clinical trials industry, today announced a multi-year global Enterprise Agreement with a Top 5 CRO. The contract includes independent trial design and use of DATATRAK ONE^® Unified Experience™ eClinical solutions for Late Phase studies.

"We continue to see growth in demand for our solutions and services across all trial phases," said Laurence P. Birch, Chairman and CEO, DATATRAK. "With our newest Enterprise Agreement CRO partner the focus is on late phase trials. Partnering with this global CRO will expand awareness of how DATATRAK uniquely addresses the evolving needs of late phase trials including ease of use, configurability, advanced reporting and flexible pricing." 

DATATRAK is a worldwide technology and consulting company delivering eClinical solutions and related services for the clinical trials industry. The company delivers a portfolio of software solutions through the unified eClinical^® platform, safely accelerating clinical research, from Concept to Cure^®.

Join DATATRAK Thought Leaders:

• Twitter
• LinkedIn
• SlideShare
• The DATATRAK Blog

Tweet: Top 5 CRO enters global multi-year Enterprise Agreement for late phase #eClinical solutions http://bit.ly/1vNrybk

About DATATRAK International, Inc.
DATATRAK International is a worldwide technology and services company delivering unified eClinical^® solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK ONE^® software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Preclinical and Phase I - Phase IV drug and device studies in multiple languages throughout the world. DATATRAK is located in Cleveland, Ohio; Bryan, Texas; Cary (RTP), North Carolina, Chicago, Illinois; and London, England.  For more information, visit http://www.datatrak.com.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements
are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on November 13, 2014 announcing its results for the third quarter 2014. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/datatrak-and-top-5-cro-enact-multi-year-enterprise-agreement-300004285.html

SOURCE DATATRAK International, Inc.

Copyright 2014 PR Newswire